No Data
CRMI (08158.HK) signed a leasing agreement with Positron.
Grace Covenant, November 1st - China Regenerative Medicine (08158.HK) announced that on November 1, 2024, the company's wholly owned subsidiary HKIRC and CRMI (Hong Kong) (as tenant) entered into a lease agreement with independent third party Zhengxin (as landlord), accordingly, Zhengxin agreed to lease the property to the company.
CRMI: Interim Report 2024
crmi (08158) announced its interim results, with a net profit of 16.828 million Hong Kong dollars, a year-on-year increase of 31.86%.
crmi (08158) announced its mid-year performance in 2024, with a profit of 59.785 million Hong Kong dollars, a year-on-year decrease...
CRMI: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
CRMI (08158.HK): Zeng Haoxian resigns as non-executive director.
China Regenerative Medicine (08158.HK) announced on August 21st that Zeng Haoxian has submitted his resignation as a non-executive director due to his intention to devote more time and energy to his other personal businesses, effective from August 20, 2024. After Zeng Haoxian's resignation, he will no longer be a member of the remuneration committee under the board of directors.
CRMI: SUPPLEMENTAL ANNOUNCEMENTIN RELATION TO THE 2023 ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023
No Data
No Data